Exploratory CSII Trial on Erectile Dysfunction in T2DM Patients (ECSIITED)
|ClinicalTrials.gov Identifier: NCT01468519|
Recruitment Status : Completed
First Posted : November 9, 2011
Last Update Posted : December 11, 2014
|Condition or disease||Intervention/treatment||Phase|
|Diabetes Mellitus, Type 2 Erectile Dysfunction||Drug: Insulin||Phase 4|
Background Erectile dysfunction (ED) is a common form of organic sexual dysfunction in males with diabetes, with estimated incidence rates between 35 and 75%. Fifty percent of men with diabetes are afflicted with ED within 10 years of their diagnosis. Long-term poor glycemic control increases the risk ED. Neuropathy is a major contributor to diabetic ED. Other causes of ED in diabetes include vascular disease, metabolic control, nutrition, endocrine disorders, psychogenic factors, and drugs.
Continuous Sub-cutaneous Insulin Infusion The Continuous Subcutaneous Insulin Infusion (CSII) Pump (insulin pump for short) is a pager-sized device which can be connected to the body through an infusion set so as to deliver insulin continuously. It consists of a disposable reservoir for insulin, a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system which connects the insulin reservoir to the cannula. Insulin pump therapy by itself is not a new therapy for diabetes mellitus. It is an alternative delivery mechanism for administration of insulin and is found to be superior to ordinary syringes and insulin pens. Insulin pumps were popularly used in T1DM but nowadays insulin pumps are commonly used in T2DM patients as well.
A guideline for use of insulin pumps in India has been recently published in Diabetes Technology and Therapeutics journal, which included participation from Jothydev's Diabetes Center.
Although comparatively costly, advantages of CSII over other modes of insulin delivery include better glycemic control, fewer hypoglycemic episodes, and improved quality of life. Our own center has reported a significant reduction in HbA1c when subjects in multiple daily insulin switched to CSII.
Relevant Clinical Data In the aforementioned study of CSII in Type 2 diabetes patients in our study, 83% of men reported an improvement in sexual function when queried after 6 months on CSII. The mode of improvement and magnitude of this effect is not known, and needs to be ascertained in prospective trials. The present study proposal is to corroborate the findings, and obtain clarification of effect size.
Potential Benefits & Risks The following improvements can be expected following initiation of insulin pump therapy.
- Improvement in HbA1c
- Reduction in blood sugar fluctuations
- Reduction in major and minor hypoglycemic episodes
- Reduction in total daily dose of insulin
- Improvement in QOL
The following are some risks/disadvantages of using insulin pump therapy
- Cost of pumps and consumables is higher than other modes of insulin delivery
- There is a risk of infection if the cannula is not changed once in every three days.
- Improper use of insulin pump boluses can lead to insulin stacking and low sugars.
Proper patient education and monitoring will be part of the study to overcome the risks of insulin pump therapy.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Effects of Continuous Subcutaneous Insulin Infusion (CSII) on Erectile Dysfunction in T2DM Patients: A Prospective, Exploratory, Controlled Trial|
|Study Start Date :||January 2012|
|Actual Primary Completion Date :||September 2014|
|Actual Study Completion Date :||November 2014|
continuous subcutaneous insulin infusion
Insulin via continuous subcutaneous insulin infusion
Active Comparator: MDI
multiple daily insulin injections
insulin via multiple daily injections
- Change in total International Index of Erectile Function (IIEF) score from baseline to six months [ Time Frame: baseline and six months ]IIEF quetionnaire is a standardised and validated 15-item self-evaluation scale that provides pre-post treatment clinic evaluations of erectile function, orgasmic function, sexual desire, satisfaction in sexual intercourse and general satisfaction
- Global assessment question on erectile function [ Time Frame: baseline and 6 months ]Global assessment question (GAQ), "Has the treatment you have been having improved your erections? (yes/no)."
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01468519
|Jothydev's Diabetes & Research Center|
|Thiruvananthapuram, Kerala, India, 695032|
|Principal Investigator:||Jothydev Kesavadev, MD||Jothydev's Diabetes & Research Center|
|Study Chair:||Gopika Krishnan, BPHARM||Jothydev's Diabetes & Research Center|